Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

173.79 -0.21 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
48 49 Next >
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
P/E Ratio Insights for Biogen
Via Benzinga
Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8
Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move. 
Via Talk Markets
Biogen Unusual Options Activity
Via Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of  
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Eli Lilly Stock Is Bolting Higher Today
Lilly's Alzheimer's disease candidate might be a best-in-class option for patients. 
Via The Motley Fool
Biogen Unusual Options Activity For May 03
Via Benzinga
Looking At Biogen's Recent Unusual Options Activity
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
Via Benzinga
Biogen Earnings Perspective: Return On Capital Employed
Via Benzinga
Another Sucess In Alzheimer’s Disease
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
Eli Lilly is focusing on proteins associated with Alzheimer's disease. 
Via Investor's Business Daily
Microsoft, Snap And 2 Other Stocks Insiders Are Selling
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
These Analysts Revise Price Targets On Biogen Following Q1 Results
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter. 
Via Benzinga
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Biogen On The Hunt
Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena? 
Via Talk Markets
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in... 
Via Benzinga
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
From Biogen Inc.
Via GlobeNewswire
What's Going On With Biogen Stock Tuesday?
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
Biogen Inc. Beats Q1 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $3.40 per share. 
Via Talk Markets
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
The company is hopeful for maintenance dosing and a new injection of the drug. 
Via Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.